These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 19451538

  • 1. Quantitative risk-benefit analysis of natalizumab.
    Steiner I.
    Neurology; 2009 May 19; 72(20):1791-2; author reply 1791-2. PubMed ID: 19451538
    [No Abstract] [Full Text] [Related]

  • 2. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep 11; 48(1243):76. PubMed ID: 16977289
    [No Abstract] [Full Text] [Related]

  • 3. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
    Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR.
    Neurology; 2007 May 01; 68(18):1524-8. PubMed ID: 17470756
    [Abstract] [Full Text] [Related]

  • 4. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R.
    Arch Neurol; 2010 Nov 01; 67(11):1391-4. PubMed ID: 20625069
    [Abstract] [Full Text] [Related]

  • 5. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab.
    Hartung HP.
    Lancet Neurol; 2009 Jan 01; 8(1):28-31. PubMed ID: 19081511
    [No Abstract] [Full Text] [Related]

  • 6. Natalizumab for relapsing multiple sclerosis.
    Jeffery DR.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742008
    [No Abstract] [Full Text] [Related]

  • 7. Natalizumab for relapsing multiple sclerosis.
    Meyer MA.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742009
    [No Abstract] [Full Text] [Related]

  • 8. [New drugs; natalizumab].
    van Bronswijk H, Dubois EA, van Gerven JM, Cohen AF.
    Ned Tijdschr Geneeskd; 2008 Mar 01; 152(9):499-500. PubMed ID: 18389881
    [Abstract] [Full Text] [Related]

  • 9. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 01; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 10. Interruption of natalizumab therapy for multiple sclerosis: what are the risks?
    Naismith RT, Bourdette D.
    Neurology; 2011 May 31; 76(22):1854-5. PubMed ID: 21543735
    [No Abstract] [Full Text] [Related]

  • 11. Natalizumab for relapsing multiple sclerosis.
    Tenser RB.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16738278
    [No Abstract] [Full Text] [Related]

  • 12. Rituximab in relapsing-remitting multiple sclerosis.
    Schrijver HM.
    N Engl J Med; 2008 Jun 12; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
    [No Abstract] [Full Text] [Related]

  • 13. Iatrogenic immunosuppression with biologics in MS: expecting the unexpected?
    Stüve O, Wiendl H.
    Neurology; 2009 Oct 27; 73(17):1346-7. PubMed ID: 19776376
    [No Abstract] [Full Text] [Related]

  • 14. Natalizumab for multiple sclerosis: a complicated treatment.
    Keegan BM.
    Lancet Neurol; 2011 Aug 27; 10(8):677-8. PubMed ID: 21777819
    [No Abstract] [Full Text] [Related]

  • 15. Natalizumab and progressive multifocal leukoencephalopathy.
    Adelman B, Sandrock A, Panzara MA.
    N Engl J Med; 2005 Jul 28; 353(4):432-3. PubMed ID: 15947083
    [No Abstract] [Full Text] [Related]

  • 16. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Warnke C, Adams O, Kieseier BC.
    N Engl J Med; 2009 Dec 17; 361(25):2489; author reply 2489-90. PubMed ID: 20050216
    [No Abstract] [Full Text] [Related]

  • 17. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Dec 17; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 18. Patients at risk.
    Drazen JM.
    N Engl J Med; 2005 Jul 28; 353(4):417. PubMed ID: 15947081
    [No Abstract] [Full Text] [Related]

  • 19. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.
    Berger JR, Koralnik IJ.
    N Engl J Med; 2005 Jul 28; 353(4):414-6. PubMed ID: 15947082
    [No Abstract] [Full Text] [Related]

  • 20. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
    Alvarez-Cermeño JC, Masjuan J, Villar LM.
    N Engl J Med; 2005 Oct 20; 353(16):1744-6; author reply 1744-6. PubMed ID: 16240475
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.